A thrombin inhibitor
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Bivalirudin

Item No. 23035

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-α-aspartyl-L-phenylalanyl-L-α-glutamyl-L-α-glutamyl-L-isoleucyl-L-prolyl-L-α-glutamyl-L-α-glutamyl-L-tyrosyl-L-leucine
CAS Number
128270-60-0
Molecular Formula
C98H138N24O33
Formula Weight
2180.3
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlPBS (pH 7.2): 10 mg/ml
λmax
278 nm
SMILES
N[C@@H](C(N1[C@H](C(N[C@@H](CCCNC(N)=N)C(N2[C@H](C(NCC(NCC(NCC(NCC(N[C@@H](CC(N)=O)C(NCC(N[C@@H](CC(O)=O)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@]([C@@H](C)CC)([H])C(N4CCC[C@H]4C(N[C@@H](CCC(O)=O)C(N[C@@H](CCC(O)=O)C(N[C@H](C(N[C@@H](CC(C)C)C(O)=O)=O)CC5=CC=C(O)C=C5)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC2)=O)=O)CCC1)=O)CC6=CC=CC=C6
InChi Code
InChI=1S/C98H138N24O33/c1-5-52(4)82(96(153)122-39-15-23-70(122)92(149)114-60(30-34-79(134)135)85(142)111-59(29-33-78(132)133)86(143)116-64(43-55-24-26-56(123)27-25-55)89(146)118-67(97(154)155)40-51(2)3)119-87(144)61(31-35-80(136)137)112-84(141)58(28-32-77(130)131)113-88(145)63(42-54-18-10-7-11-19-54)117-90(147)66(45-81(138)139)110-76(129)50-107-83(140)65(44-71(100)124)109-75(128)49-106-73(126)47-104-72(125)46-105-74(127)48-108-91(148)68-21-13-38-121(68)95(152)62(20-12-36-103-98(101)102)115-93(15
InChi Key
OIRCOABEOLEUMC-GEJPAHFPSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    5 mg

    $69

    Add

    10 mg

    $102

    Add

    25 mg

    $233

    Add

    50 mg

    $393

    Add
    Product Description

    Bivalirudin is an inhibitor of α- and ζ-thrombin (Kis = 2.56 and 1.84 nM, respectively), enzymes that exhibit high fibrinogen-clotting activities.1 It is selective for α- and ζ-thrombin, lacking activity at trypsin and γ-thrombin, which lacks clotting activity, at a >1,000-fold excess of bivalirudin. Bivalirudin inhibits α-thrombin-stimulated activation of the clotting factors Factor X, Factor V, and prothrombin in contact-activated plasma at a concentration of 0.1 μM.2 Administration of bivalirudin (0.5-1.5 mg/kg, i.v.) reduces platelet deposition in a rat carotid endarterectomy model in a dose-dependent manner.3 Formulations containing bivalirudin have been used to prevent ischemic events during angioplasty for thrombus-containing lesions.4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Witting, J.I., Bourdon, P., Brezniak, D.V., et al. Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem J. 283(Pt 3), 737-743 (1992).

    2. Ofosu, F.A., Fenton, J.W., II, Maraganore, J.M., et al. Inhibition of the amplification reactions of blood coagulation by site-specific inhibitors of α-thrombin. Biochem J. 283(Pt 3), 893-897 (1992).

    3. Hamelink, J.K., Tang, D.B., Barr, C.F., et al. Inhibition of platelet deposition by combined hirulog and aspirin in a rat carotid endarterectomy model. J. Vasc. Surg. 21(3), 492-498 (1995).

    4. Shah, P.B., Ahmed, W.H., Ganz, P., et al. Bivalirudin compared with heparin during coronary angioplasty for thrombus-containing lesions. J. Am. Coll. Cardiol. 30(5), 1264-1269 (1997).